Eli Lilly | LLY - Operating Expenses


Eli Lilly reported $10.02B in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Abbott USD 9.31B 104M Mar/2026
ALKERMES USD 1.75B 1.43B Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Baxter International USD 6.04B 2.85B Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Drreddys Laboratories INR 74.33B 1.4B Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Glaxosmithkline GBP 5.34B 3.83B Mar/2026
J&J USD 17.83B 388M Jun/2026
Medtronic USD 7.72B 436M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Novo Nordisk DKK 37.21B 9.56B Mar/2026
Perrigo USD 935.6M 89.6M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Phibro Animal Health USD 361.83M 29.47M Mar/2026
Prestige Brands USD 206.12M 5.17M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 9.31B 1.2B Mar/2026
Sanofi EUR 8.98B 1.73B Mar/2026
United Therapeutics USD 5.9B 5.1B Mar/2026
Zoetis USD 3.23B 1.68B Mar/2026